|1.||Apte, Ron N: 7 articles (01/2012 - 01/2003)|
|2.||Voronov, Elena: 6 articles (01/2012 - 03/2003)|
|3.||Funahashi, Hitoshi: 6 articles (05/2009 - 01/2003)|
|4.||Sawai, Hirozumi: 6 articles (05/2009 - 01/2003)|
|5.||Takeyama, Hiromitsu: 6 articles (05/2009 - 01/2003)|
|6.||Iwakura, Yoichiro: 6 articles (12/2008 - 11/2002)|
|7.||Okada, Yuji: 5 articles (08/2008 - 01/2003)|
|8.||Manabe, Tadao: 5 articles (08/2008 - 01/2003)|
|9.||Matsuo, Yoichi: 4 articles (05/2009 - 10/2005)|
|10.||Dinarello, Charles A: 4 articles (04/2009 - 03/2003)|
07/01/1992 - "A phase I trial was undertaken because interleukin-1 alpha (IL-1 alpha) possesses antiproliferative, immunostimulatory, antiinfection, myeloprotective, and myelorestorative properties that could be beneficial in cancer treatment. "
03/01/1993 - "The data from our model systems provide a rationale for additional work to define the mechanisms of the synergistic antitumor activity of the cP plus IL-1 alpha combination and indicate that IL-1 alpha might be a useful adjunct to increase the clinical efficacy of cP-containing strategies for both sensitive and cP-resistant cancers."
06/01/1997 - "Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors."
03/01/1996 - "Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer."
02/15/1996 - "These studies suggest that the antitumor activity of IL-1 alpha may be mediated through the production of NO from tumor-derived endothelial cells."
08/12/2008 - "Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis."
01/24/2003 - "Although the HIV-1 genome in the lymphocytes was dormant under normal physiological conditions, it could be reactivated by lipopolysaccharide (LPS) administration via induction of interleukin-1alpha/beta and tumour necrosis factor-alpha. "
02/01/1999 - "Cultured fibroblasts prepared from the dental papillae of individuals of different ages produced HGF/SF at almost the same rate, but the sensitivities of the cells to interleukin-1alpha and tumour necrosis factor-alpha for the production of HGF/SF increased with age. "
01/01/1996 - "Levels of tumour necrosis factor-alpha and interleukin-1 alpha were elevated above the normal range more frequently in the eight twins who developed diabetes than in those 20 who did not (p < 0.005). "
11/01/1994 - "Interleukin-1 alpha- and beta-, interleukin-6- and tumour necrosis factor-alpha-like immunoreactivities in chronic granulomatous skin conditions."
01/01/1996 - "Study of virus dissemination in the central nervous system (CNS) showed a massive infection of main brain structures from day 4 post infection (p.i.) up to the agony stage on day 6 p.i. At the same time, IL-1 alpha concentrations increased in cortical and hippocampal homogenates, whereas no change was detected in serum. "
01/01/1990 - "In the present study, the effect of HSV-1 infection on interleukin-1 alpha and beta gene transcription in peritoneal exudate cells was investigated. "
08/01/1988 - "In this study we show that recombinant human IL-1 alpha (rhIL-1 alpha) protects both genetically resistant and susceptible strains of mice against Listeria monocytogenes infection. "
09/01/1987 - "In this study we report that treatment with recombinant murine interleukin-1 alpha (rIL-1 alpha) significantly enhanced the resistance of mice to infection by the facultative intracellular pathogen Listeria monocytogenes. "
05/01/2010 - "In contrast, the secretion of the mature form of IL-1 alpha from infected macrophages was observed in infection with wild-type L. "
08/01/2013 - "Upon skin contact to irritants, interleukin-1 alpha (IL-1α) is released in the stratum corneum as a primary step of skin inflammation. "
04/29/2010 - "Platelet interleukin-1alpha drives cerebrovascular inflammation."
11/01/2009 - "Thus, nuclear retention of IL-1 alpha may serve to limit inflammation following cell death."
11/01/2009 - "We found that IL-1 alpha is actively trafficked to the nuclei of microglia, and hence tested the hypothesis that trafficking of IL-1 alpha to the nucleus would inhibit its release following necrotic cell death, limiting sterile inflammation. "
11/01/2009 - "Nuclear retention of IL-1 alpha by necrotic cells: a mechanism to dampen sterile inflammation."
05/25/1993 - "The potent synergy of IL-1 alpha and DOX against ovarian carcinoma cells in vitro suggests that this drug combination may be effective against this disease in the clinic."
07/01/1993 - "During a phase I trial of interleukin-1 alpha (IL-1 alpha) in patients with ovarian carcinomas, the effects of this treatment on blood granulocyte respiratory burst and locomotive responses were examined. "
03/01/2001 - "The amounts of IL-1 alpha, IFN-alpha, and IFN-gamma in carcinomas in the OK group were significantly higher than in the controls (P < 0.05), and these were significantly correlated with the dThdPase activity. "
08/01/1996 - "Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease."
07/01/1995 - "Major factor of this activity was IL-1 alpha which was produced by pancreas carcinoma cells. "
|1.||Interleukin-1beta (Interleukin 1 beta)
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Interleukin-1 (Interleukin 1)
|6.||Interleukin-6 (Interleukin 6)
|7.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|8.||Messenger RNA (mRNA)
|10.||Transforming Growth Factor beta (TGF-beta)
|1.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|5.||Heterologous Transplantation (Xenotransplantation)